Working… Menu

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02364076
Recruitment Status : Active, not recruiting
First Posted : February 16, 2015
Last Update Posted : November 30, 2018
Merck Sharp & Dohme Corp.
Incyte Corporation
Information provided by (Responsible Party):
Georgetown University

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : December 2021
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 6, 2019
August 21, 2019
2 August 28, 2019
September 16, 2019
3 October 25, 2019
November 12, 2019